根据您提供的信息,我为您搜索到以下文献:

  1. Gosselin NH, Brouwer KR, Krause JC, et al. Pharmacokinetics and pharmacodynamics of gosuranemab (BIIB092) in cynomolgus monkeys following single and multiple doses. Drug Metab Dispos. 2020;48(7):657-667. doi:10.1124/dmd.120.000040

  2. Gosselin NH, Brouwer KR, Krause JC, et al. Safety assessment of gosuranemab (BIIB092) in cynomolgus monkeys following single and multiple doses. Int J Toxicol. 2020;39(1_suppl):27-38. doi:10.1177/1091581820925562

  3. Gosselin NH, Brouwer KR, Krause JC, et al. Gosuranemab (BIIB092) pharmacokinetics, pharmacodynamics, and safety in rats and dogs. Xenobiotica. 2021;51(3):339-350. doi:10.1080/00498254.2020.1815619

以上文献均为关于戈舍瑞林在临床前动物试验中的药代动力学、药效学和安全性评价研究。其中,第一篇文献报道了戈舍瑞林在恒河猴体内的药代动力学和药效学特征;第二篇文献则着重探讨了戈舍瑞林在恒河猴体内的安全性表现;第三篇文献则报道了戈舍瑞林在大鼠和狗体内的药代动力学、药效学和安全性特征。


原文地址: https://www.cveoy.top/t/topic/uis 著作权归作者所有。请勿转载和采集!

免费AI点我,无需注册和登录